MedTrace Logo

COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19

NCT04328012 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-03-24

No results posted yet for this study

Summary

In a randomized, double-blind, placebo-controlled, multi-center, Phase 2-like, investigator-directed trial, hospitalized adult patients with laboratory confirmed SARS-CoV-2 infection meeting inclusion and exclusion criteria, will be provided information on the trial, offered enrollment, and if informed consent provided, enrolled randomly in a 2:1 ratio to one of two groups: Group 1 standard care and losartan or Group 2 standard care and placebo. Patients will be followed for up to 60 days, with data collected to quantify the NCOSS over time (the primary objective), and for the trial's secondary objectives (see outcome measurements below).

Conditions

Interventions

DRUG

Losartan

administered 14 days

DRUG

Placebo

administered 14 days

Sponsors & Collaborators

  • Reid Health

    collaborator UNKNOWN

  • Goshen Health System

    collaborator OTHER

  • Bassett Healthcare

    lead OTHER

Principal Investigators

  • Daniel Freilich, MD · Bassett Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-06
Primary Completion
2021-07-01
Completion
2021-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04328012 on ClinicalTrials.gov